Three abstracts detailing preclinical and translational data on the application of next-generation alkylating Peptide-Drug Conjugates (PDCs) in glioblastoma have been accepted for poster presentation at EANO 2026. This marks the first major scientific presentations within glioblastoma with Oncopeptides’ data, an important step into a new indication with a significant unmet medical need.
In addition, Oncopeptides is proud to announce that one of the abstracts has been nominated for prestigious EANO 2026 Poster award.